RE:RE:StageZero Twitter - FAQ on the Acquisition. How is this acquisition beneficial to StageZero Life Sciences? A. Cancer tests have to be administered by a healthcare provider, preferably a physician experienced in cancer care. StageZero has now partnered with an innovative, telehealth-based Oncology/early disease group with an established presence in all 50 US states. Patients and employers/organizations will now have access to leading oncologists, patented clinical protocols for the prevention and treatment of cancer, and StageZero’s Next Generation Multi-Cancer Test Panel - Aristotle; all delivered via Telehealth. Care Oncology currently has thousands of patients they are currently working with. Additionally, employers have informed us that access to an organization such as Care Oncology is a necessary step to providing care for their employees who test positive on Aristotle. The acquisition also opens up multiple revenue streams beyond just the Aristotle test. Q. Is there a share price associated with the deal? A. There is not a share price associated with the deal. The acquisition is an all-share deal and not underpinned by a share price. Q. Who is Care Oncology? A. Care Oncology is comprised of leading scientists, oncologist and healthcare providers who have developed a proprietary protocol (COC ™) which includes a combination of medicines to deprive cancer of the nutrients it needs to grow and spread. The protocol is used to benefit patients with cancer of any stage or type. Care Oncology uses telemedicine to provide specialist clinical services across Europe and North America. They have a robust telehealth practice and networks in each of the 50 US states. In addition, they have clinics in London and Los Angeles. Q. What is the AVRT program? A. AVRT™ (pronounced Avert) is a comprehensive telehealth program that uses advanced diagnostics, proven clinical protocols and physician supervision to prevent the development of cancer and other chronic diseases. AVRT™ is available directly to consumers and employer groups who want personalized care plans to prevent cancer through early interventions. This program includes Aristotle™, StageZero’s flagship blood test that uses mRNA technology to detect 9 specific cancers in women and 6 cancers in men from a single sample of blood. The program also includes Care Oncology’s (COC™) protocol and the measurement of inflammatory markers. Patients can access this program via telehealth from anywhere in the U.S.
Consumers who want to live better, longer. This includes consumers who are concerned about developing cancer and other chronic diseases and those who believe they are at a higher risk of developing cancer. This particular program is not for current cancer patients. Employers who want to mitigate catastrophic health claims by keeping their employees healthy. Q. Who is the AVRT program target market? A. The AVRT program will be targeting two specific groups. Q. Will the AVRT program/Aristotle be available to employers? A. Yes as the AVRT program is rolled out it will be made available to our channel partners first and then rolled out more broadly. Q. Will the AVRT program be available outside of the US? A. AVRT is available in the US first, and then in the UK. StageZero is working on partnerships that will serve additional markets including Canada and the EU, as well as other global markets. Q. Why can’t I just order the Aristotle test? A. Cancer diagnostics have to be prescribed by a physician. It is a regulatory requirement. A test that is this sophisticated and life changing cannot be marketed directly to consumers without the supervision of a healthcare provider. Having a test alone, does not round out the circle of care needed to improve patient outcomes. If you get a positive test result for one of the cancers in our panel, you need a plan, and you need a care team to guide you. This is why the acquisition of Care Oncology is so important to the success of Aristotle.